Dergiler / Journal of Basic and Clinical Health Sciences / 2018 / Cilt: 2 - Sayı: 3

Effects of Biologic Therapies for Cutaneous Inflammatory Diseases in HIV-Infected Individuals: Reliable or Not?

Sayfa
61–67
Yayın Tarihi
2022-10-19
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Further multicentre randomised controlled trials about the use of biologic agents in these patient groups are necessary.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Purpose: Patients with cutaneous inflammatory diseases often present with more aggressive and refractory clinical course in the presence ofaccompanying human immunodeficiency virus (HIV) infection.
📊
Temel Bulgular & Veri:The use of biologic agents in HIV positive patients is conflicting because such treatment can lead to increase the risk of infection andmalignancy in already immunocompromised patients.
💡
Sonuç & Katkı:Further multicentre randomised controlled trials about the use of biologic agents in these patient groups are necessary.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Purpose: Patients with cutaneous inflammatory diseases often present with more aggressive and refractory clinical course in the presence ofaccompanying human immunodeficiency virus (HIV) infection. Therefore, biologic therapies may be needed to improve outcomes of thesepatients. The use of biologic agents in HIV positive patients is conflicting because such treatment can lead to increase the risk of infection andmalignancy in already immunocompromised patients. On the other hand, some researchers have recommended that HIV management shouldalso include the blockade of tumour necrosis factor-alpha (TNF-α). We discuss the reliability and effectiveness of biologic therapies for patientswith cutaneous inflammatory diseases and accompanying HIV infection.Methods: The Medline literature database search through PubMed using the key words ‘human immunodeficiency virus’, ‘cutaneousinflammatory diseases’, ‘TNF-α inhibitor’, ‘biologic therapy’, ‘biologic treatment’, ‘adalimumab’, ‘etanercept’, ‘infliximab,’ ‘ustekinumab’, and‘rituximab’ was performed. Literature data associated with biologic therapies of cutaneous inflammatory diseases in HIV-positive patients wereevaluated.Results: The literature search identified a total of 17 patients with HIV infection receiving biologic therapy for cutaneous inflammatory diseases(psoriasis, psoriatic arthritis, hidradenitis suppurativa and pemphigus vulgaris) from two case series and 12 case reports.Conclusion: In HIV-infected patients with severe and refractory cutaneous inflammatory diseases, biologic therapies should only be reservedfor those whom HIV status is stable at baseline. Screening for tuberculosis prior to treatment and close monitoring for potential side effects aremandatory. Further multicentre randomised controlled trials about the use of biologic agents in these patient groups are necessary.

🔖

Bu Makaleye Atıf Yap

Akarsu, S., Avcı, C. (2022). Effects of Biologic Therapies for Cutaneous Inflammatory Diseases in HIV-Infected Individuals: Reliable or Not?. Journal of Basic and Clinical Health Sciences, Cilt: 2 - Sayı: 3, 61–67. https://ajindex.com/articles/560623

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Fernandez JM, Fernandez AP, Lang DM. Biologic therapy in the treatment of chronic skin disorders. Immunol Allergy Clin North Am 2017;37:315–327. [CrossRef] 2. Fink DL, Hedley L, Miller RF. Systematic review of the efficacy and safety of biological therapy for inflammatory conditions in HIVinfected individuals. Int J STD AIDS 2017;28:110–119. [CrossRef] 3. Liang SJ, Zheng QY, Yang YL, Yang Y, Liu CY. Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: a case-based review. Rheumatol Int 2017;37:1207–1212. [CrossRef] 4. Han G. Biologics in dermatology beyond psoriasis. Cutis 2014;93:E21-E27. 5. Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--update 2015--short version--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015;29:2277–2294. [CrossRef] 6. Rustin MHA. Long-term safety of biologics in the treatment of moderateto-severe plaque psoriasis: review of current data. Br J Dermatol 2012;167:3–11. [CrossRef] 7. Gallitano SM, McDermott L, Brar K, Lowenstein E. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. J Am Acad Dermatol 2016;74:974–980. [CrossRef] 8. Husein-ElAhmed H, Fernandez-Pugnaire MA, Ruiz-Carrascosa JC. Severe hidradenitis suppurative in an HIV-positive male: use of multiple treatment modalities, including tumor necrosis factor blockade. AIDS Patient Care STDS 2011;25:507–508. [CrossRef] 9. Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study at the university-based hospital. Int J Rheum Dis 2009;12:118–124. [CrossRef] 10. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;16:1–81. [CrossRef] 11. Gaylis NB. Long-term follow-up of an HIV-infected patient with reactive arthritis treated with infliximab. J Clin Rheumatol 2012;18:153–154. [CrossRef] 12. Habib SF, Hasan MZ, Salam I. Infliximab therapy for HIV positive Crohn’s disease: a case report. J Crohs Colitis 2009;3:302–304. [CrossRef] 13. Ito M, Baba M, Sato A, et al. Tumor necrosis factor enhances replication of human immunodeficiency virus (HIV) in vitro. Biochem Biophys Res Commun 1989;158:307–312. [CrossRef] 14. Butera ST, Roberts BD, Folks TM. Ligand passing by the p75 tumour necrosis factor receptor enhances HIV-1 activation. Cytokine 1996;8:745–